Richard Cathomas, MD, on MIBC: Perioperative Intravesical Recombinant BCG Combined With Chemoimmunotherapy
ASCO 2026
Richard Cathomas, MD, of Cantonal Hospital Graubünden, reviews results from the primary analysis of SAKK 06/19, an open-label single arm phase II trial, which found that the combination of intravesical recombinant bacillus Calmette-Guérin (BCG) with atezolizumab, cisplatin, and gemcitabine was feasible and safe without unexpected toxicities and demonstrates promising efficacy in patients with muscle-invasive bladder cancer (MIBC) (Abstract 4503).
The ASCO Post Staff
Ronald C. Chen, MD, MPH, FASCO, of the University of Kansas Medical Center, presents health-related quality of life (HRQoL) data from the AMBASSADOR trial, which showed that in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery, adjuvant pembrolizumab for 1 year approximately doubled disease-free survival, causes fatigue and dyspnea which modestly impacted physical function and ability to perform certain roles (such as work and hobbies), without impact on overall quality of life (Abstract 4513).
The ASCO Post Staff
Sara A. Hurvitz, MD, FACP, of Fred Hutchinson Cancer Center, provides an update focusing on progression-free survival after next line of treatment and subsequent therapies among patients enrolled in the ASCENT-03 trial. The study compared sacituzumab govitecan vs chemotherapy in patients with previously untreated metastatic triple-negative breast cancer (Abstract 1001).
Dai Chihara, MD, of The University of Texas MD Anderson Cancer Center, reviews results from an open-label, single-arm, phase II trial that investigated the combination of epcoritamab with R-miniCVP (rituximab, cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) classified as unfit or frail per geriatric assessment or not eligible for anthracycline chemotherapy due to reduced ejection function or prior exposure (Abstract 7002).
Jennifer A. Woyach, MD, of The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University, discusses the ongoing, actively recruiting ROCKET-CLL trial, which is a phase III study aiming to compare the efficacy of rocbrutinib vs pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have been pretreated with Bruton tyrosine kinase covalent inhibitors (Abstract TPS7100).
For more information about the trial, visit ClinicalTrials.gov (identifier NCT07342478).
The ASCO Post Staff
Shubham Pant, MD, MBBS, of The University of Texas MD Anderson Cancer Center, discusses the practice-changing results of the phase III RASolute 302 study, which showed that daraxonrasib doubled median overall survival compared with standard chemotherapy in pretreated metastatic pancreatic cancer (Abstract LBA5).
